Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
| العنوان: | Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients |
|---|---|
| المؤلفون: | Laura Cotiguala, Katie McMurry, Sarah Tischer, Sonya Anderson, Jeong Mi Park |
| المصدر: | Annals of Pharmacotherapy. 55:496-508 |
| بيانات النشر: | SAGE Publications, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Drug, medicine.medical_specialty, media_common.quotation_subject, medicine.medical_treatment, 030209 endocrinology & metabolism, Kidney transplant, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Diabetes management, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Pharmacology (medical), 030212 general & internal medicine, Disease management (health), Sodium-Glucose Transporter 2 Inhibitors, Antidiabetic agents, media_common, Clinical Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Disease Management, Immunosuppression, medicine.disease, Kidney Transplantation, Transplant Recipients, Transplantation, Diabetes Mellitus, Type 2, business |
| الوصف: | Objective This systematic review describes the efficacy, safety, and drug interactions of dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose transport protein 2 (SGLT2) inhibitors in kidney transplant recipients (KTRs). Data Sources Articles were identified by English-language MEDLINE search, published prior to May 2020, using the terms kidney transplant, OR PTDM, OR NODAT, AND metformin, OR DPP4, OR GLP1, OR SGLT2. Study Selection and Data Extraction All selected studies were included if the study population was composed of adult KTRs who were diagnosed with either impaired glucose tolerance, diabetes mellitus (DM), new-onset diabetes after transplant (NODAT), or posttransplantation diabetes mellitus (PTDM). Data Synthesis In KTRs, there is evidence for safety with DPP-4 inhibitors, GLP-1 RAs, and SGLT2 inhibitors. However, urinary tract infections and a slight initial decrease in renal function may limit use of SGLT2 inhibitors. As compared with the nontransplant type 2 DM population, SGLT2 inhibitors are not as efficacious in KTRs. Relevance to Patient Care and Clinical Practice This review provides an overview of the current literature on newer antidiabetic agents, addressing efficacy, safety, and drug interactions to help guide clinical decision-making for their use in KTRs. Conclusion Newer antidiabetic agents have been recommended by the American Diabetes Association for potential cardiovascular, renal, and hypoglycemic benefits. Particular agents, such as DPP-4 inhibitors and GLP-1 RAs may play a role in correcting PTDM-related defects. Clinicians need to take into account both patient-specific and drug-specific characteristics when initiating these agents in KTRs. |
| تدمد: | 1542-6270 1060-0280 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20082b31ae990b20d830ce2100aa193e https://doi.org/10.1177/1060028020951955 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....20082b31ae990b20d830ce2100aa193e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15426270 10600280 |
|---|